These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15568633)

  • 21. Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus.
    Karges B; Muche R; Riegger I; Moritz M; Heinze E; Debatin KM; Wabitsch M; Karges W
    Clin Ther; 2006 Dec; 28(12):2094-101. PubMed ID: 17296465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Experiences with human insulin. Results of a study in 1,267 diabetics previously treated with animal insulin].
    Hösl W; Kloss G; Büchel CG
    Fortschr Med; 1986 Oct; 104(38):721-4. PubMed ID: 3536698
    [No Abstract]   [Full Text] [Related]  

  • 23. Optimizing insulin therapy in patients with type 1 and type 2 diabetes mellitus: optimal dosing and timing in the outpatient setting.
    Hahr AJ; Molitch ME
    Am J Ther; 2008; 15(6):543-50. PubMed ID: 19127139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products.
    Bullano MF; Al-Zakwani IS; Fisher MD; Menditto L; Willey VJ
    Curr Med Res Opin; 2005 Feb; 21(2):291-8. PubMed ID: 15802000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW
    Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Short-acting and depot insulin analogs. Advantages and disadvantages in comparison with current insulin types].
    Lehnert H; Klose S; Kerner W
    Internist (Berl); 2001 Apr; 42 Suppl 1():S29-42. PubMed ID: 11370610
    [No Abstract]   [Full Text] [Related]  

  • 27. [Insulin therapy in type 2 diabetes. Insured patients would be willing to pay for added benefits].
    MMW Fortschr Med; 2008 Dec; 150(49-50):56-7. PubMed ID: 19133372
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study: response to Porcellati et al.
    Banarer S
    Diabetes Care; 2008 Mar; 31(3):e16; author reply e17. PubMed ID: 18308679
    [No Abstract]   [Full Text] [Related]  

  • 29. Insulin detemir--a new basal insulin analog.
    Goldman-Levine JD; Lee KW
    Ann Pharmacother; 2005 Mar; 39(3):502-7. PubMed ID: 15657117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rational use of insulin analogues in the treatment of type 1 diabetes mellitus.
    Bolli GB
    Pediatr Endocrinol Rev; 2003 Sep; 1(1):9-21. PubMed ID: 16437009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin detemir: a new basal insulin analogue.
    Soran H; Younis N
    Diabetes Obes Metab; 2006 Jan; 8(1):26-30. PubMed ID: 16367879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Insulin analogs. More precise control for diabetic patients is possible].
    MMW Fortschr Med; 2001 Jan; 143(3):52-3. PubMed ID: 11215346
    [No Abstract]   [Full Text] [Related]  

  • 33. Inhaled insulin: Exubera.
    Odegard PS; Capoccia KL
    Ann Pharmacother; 2005 May; 39(5):843-53. PubMed ID: 15827072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of insulin aspart and regular insulin in elderly patients with type 2 diabetes.
    Meneilly GS
    Diabetes Obes Metab; 2007 Sep; 9(5):754-5. PubMed ID: 17697065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update in diabetes management.
    Cranwell-Bruce LA
    Medsurg Nurs; 2009; 18(1):51-3; quiz 54. PubMed ID: 19331300
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study.
    Porcellati F; Rossetti P; Busciantella NR; Marzotti S; Lucidi P; Luzio S; Owens DR; Bolli GB; Fanelli CG
    Diabetes Care; 2007 Oct; 30(10):2447-52. PubMed ID: 17623819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The new insulins].
    Krzentowski G
    Rev Med Brux; 2005 Sep; 26(4):S241-5. PubMed ID: 16240869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
    Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA
    Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes: the role of insulin analogs.
    Rossetti P; Porcellati F; Bolli GB; Fanelli CG
    Diabetes Care; 2008 Feb; 31 Suppl 2():S113-20. PubMed ID: 18227470
    [No Abstract]   [Full Text] [Related]  

  • 40. [Does insulin glargin (lantus) lead to a progression in diabetic retinopathy?].
    Meyer CH; Kroll P; Hammes HP
    Klin Monbl Augenheilkd; 2005 Apr; 222(4):353-4. PubMed ID: 15844050
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.